GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Taisho Pharmaceutical Holdings Co Ltd (TSE:4581) » Definitions » Total Assets

Taisho Pharmaceutical Holdings Co (TSE:4581) Total Assets : 円1,005,463 Mil (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Taisho Pharmaceutical Holdings Co Total Assets?

Taisho Pharmaceutical Holdings Co's Total Assets for the quarter that ended in Dec. 2023 was 円1,005,463 Mil.

During the past 12 months, Taisho Pharmaceutical Holdings Co's average Total Assets Growth Rate was -1.30% per year. During the past 3 years, the average Total Assets Growth Rate was -4.20% per year. During the past 5 years, the average Total Assets Growth Rate was 1.70% per year. During the past 10 years, the average Total Assets Growth Rate was -0.20% per year.

During the past 13 years, Taisho Pharmaceutical Holdings Co's highest 3-Year average Total Assets Growth Rate was 8.80%. The lowest was -7.40%. And the median was 1.90%.

Total Assets is connected with ROA %. Taisho Pharmaceutical Holdings Co's annualized ROA % for the quarter that ended in Dec. 2023 was 1.15%. Total Assets is also linked to Revenue through Asset Turnover. Taisho Pharmaceutical Holdings Co's Asset Turnover for the quarter that ended in Dec. 2023 was 0.08.


Taisho Pharmaceutical Holdings Co Total Assets Historical Data

The historical data trend for Taisho Pharmaceutical Holdings Co's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taisho Pharmaceutical Holdings Co Total Assets Chart

Taisho Pharmaceutical Holdings Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 821,782.00 864,974.00 876,923.00 888,159.00 941,490.00

Taisho Pharmaceutical Holdings Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 946,836.00 941,490.00 966,331.00 1,000,111.00 1,005,463.00

Taisho Pharmaceutical Holdings Co Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Taisho Pharmaceutical Holdings Co's Total Assets for the fiscal year that ended in Mar. 2023 is calculated as

Total Assets=Total Equity (A: Mar. 2023 )+Total Liabilities (A: Mar. 2023 )
=809343+132147
=941,490

Taisho Pharmaceutical Holdings Co's Total Assets for the quarter that ended in Dec. 2023 is calculated as

Total Assets=Total Equity (Q: Dec. 2023 )+Total Liabilities (Q: Dec. 2023 )
=857295+148168
=1,005,463

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Taisho Pharmaceutical Holdings Co  (TSE:4581) Total Assets Explanation

Total Assets is connected with ROA %.

Taisho Pharmaceutical Holdings Co's annualized ROA % for the quarter that ended in Dec. 2023 is

ROA %=Net Income (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=11492/( (1000111+1005463)/ 2 )
=11492/1002787
=1.15 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Taisho Pharmaceutical Holdings Co's Asset Turnover for the quarter that ended in Dec. 2023 is

Asset Turnover
=Revenue (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=83576/( (1000111+1005463)/ 2 )
=83576/1002787
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Taisho Pharmaceutical Holdings Co Total Assets Related Terms

Thank you for viewing the detailed overview of Taisho Pharmaceutical Holdings Co's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Taisho Pharmaceutical Holdings Co (TSE:4581) Business Description

Traded in Other Exchanges
Address
3-24-1 Takada, Toshima-ku, Tokyo, JPN, 170-8655
Taisho Pharmaceutical Holding Co Ltd is a specialty and generic drug manufacturing company. The company maintains two operational segments, Self-Medication and Prescription Pharmaceuticals. The vast majority of Taisho's revenue is derived from its Self-Medication segment. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities. The vast majority of sales are generated by sales to external customers in Japan.

Taisho Pharmaceutical Holdings Co (TSE:4581) Headlines

No Headlines